N/A N=40 Reproductive Life Planning for Women With Mental Illness
Psychotic Disorders · Mood Disorders · Stress Disorders, Post-Traumatic
Primary: Reproductive Life Goal Behavioral Intentions — 3.6; 2.7; 3.3; 3.0 score on scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=54 General Anesthesia Emergence Induced by Methylphenidate
Delayed Emergence From Anesthesia
Primary: Emergence Time — 9; 9 minutes
N/A N=56 Novel Medication as a Potential Smoking Cessation Aid
Tobacco Use Disorder
Primary: Percent of Days of Confirmed Abstinence (Out of 5 Maximum) — 46.9; 42.0 percentage of days non-smoking
Phase 2 N=96 Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
Non Alcoholic Fatty Liver Disease
Primary: Change in Serum ALT (Alanine Aminotransferase) From Baseline to Week 16 — -16.3; -6.9; -10.1 U/L — p=0.5946
Phase 3 N=1,331 BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Multiple Sclerosis
Primary: Annualized Rate of Confirmed Relapses — 0.344; 0.283; 0.255 relapse per year — p=0.0746
Phase 1 N=174 Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1 — 0; 0; 0; 0 Participants
N/A N=70 Lifestyle Enhancement for ADHD Program
ADHD
Primary: Moderate to Vigorous Physical Activity (MVPA) — 53.1; 51.8 Moderate-Vigorous Minutes per day
Phase 4 N=25 Contact: Developing New Clinical Management Strategies
Major Depressive Disorder
Primary: Change From Baseline Hamilton Rating Scale for Depression 24-Item Scale to Study Completion (8 Weeks) — 1.33; 11.4; 5.33; 9.25 score on a scale — p=0.292
N/A N=23 Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
Treatment Resistant Depression
Primary: Percent Change in the Montgomery Asberg Depression Rating Scale (MADRS) Score From Pre-treatment to 1-month — -67.07 Percentage of change in score
Phase 2 N=149 Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
Sars-CoV2 · COVID-19
Primary: Time Until Cessation of Oral Shedding of SARS-CoV-2 Virus — 13; 14 days — p=0.24
Phase 3 N=517 Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 — 12.2; 11.0 Scores on a scale — p=0.099
Phase 2 N=425 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Objective Response Rate (ORR) as Determined by Blinded Independent Central Review (BIRC) - Platinum Refractory Subgroup — 13.2; 18.3 percentage of participants — p=0.2897
N/A N=92 Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia
Hypoxic Ischaemic Encephalopathy
Primary: Lactate (Lac) / N Acetyl Aspartate (NAA) Ratio on Magnetic Resonance Spectroscopy — 0.25; 0.28 ratio
N/A N=9 Histological Study to Assess Safety and Efficacy of the TempSure Firm for Non-Invasive Lipolysis
Non-invasive Lipolysis
Primary: Histology of Biopsy — 2; 2 Participants
N/A N=11 Return to Everyday Activities in the Community and Home
Aging · Activity · Lifestyle
Primary: REACH Session Feedback — 5.94 score on a scale